Adaptive Reuse is Gaining Momentum to Tackle the Housing Crisis

 

With the housing market booming and driving up home prices in the US, “adaptive reuse,” or the buying up of large commercial spaces to convert into affordable housing, is gaining momentum. For instance, California’s Project Homekey purchased and converted entire hotels and office buildings into thousands of affordable units — more than 6,000 new units to be exact.

Frederick Becker, associate professor at York College of Pennsylvania, described a few challenges associated with adaptive reuse with Host Hillary Kennedy:

Transient vs. Long-Term Residency

While guests are transient at hotels and other commercial buildings, residents tend to live in a home for a longer amount of time. Converting a commercial space to a residential building changes the legal and operational status to tenant, which poses its own special problems.

Location

Hotels are typically located in high-traffic, convenient locations, like near highways and cities, which isn’t always the most ideal for long-term residents.

Construction

Unless if the space is already outfitted with a full kitchen, like an extended stay, converting a commercial space into an apartment could be difficult and costly.

While travel demand continues to fluctuate due to the pandemic, hotels still continue to provide plenty of value to its community. For instance, Becker commented on how hotels provide individuals an opportunity to explore different places now that more people are able to work remote.

More Stories Like This:

How Is a ‘Wild West’ Housing Market Creating Moving and Inventory Challenges?

What in the World is Going on with the United States Housing Market?

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More